Idorsia's once-daily TRYVIO™ (aprocitentan) is now available in the U.S., advancing treatment options for millions of patients with difficult-to-control hypertension
Viatris Inc. (NASDAQ:NASDAQ:VTRS) Q1 2024 Earnings Call Transcript May 9, 2024 8:30 AM ETCompany ParticipantsBill Szablewski - Head of Capital MarketsScott...